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INTRODUCTION
a-adrenoceptor (AR) antagonists were first used in the uro-
logic field to treat patients with lower urinary tract symp-
toms suggestive of benign prostate hyperplasia (BPH). Sub-
sequently, many trials have provided evidence of the efficacy
and tolerability of a-AR antagonists in male patients with
lower urinary tract symptoms (LUTS). However, although
a1-AR antagonist therapy has become an established treat-
ment method for LUTS in men, little is known about its
effects in women. 
Female voiding dysfunction encompasses those with diffi-
culty emptying the bladder whether due to an inability to
contract the detrusor effectively, bladder outflow obstruction,
loss of detrusor-sphincter coordination, or a combination of
these. The prevalence of voiding phase dysfunction in women
has been reported to be 2-25.5% among women referred for
the evaluation of lower urinary tract symptoms (1). Moreover,
recent studies show that a1-AR antagonists effectively im-
prove symptoms and voiding parameters in women with func-
tional bladder outlet obstruction or detrusor underactivity
(2-4). Because a1-ARs appear to play roles in lower urinary
tract function at multiple sites and levels, including the blad-
der neck and external urethral sphincter, and because these
non-prostate effects should be gender-independent, it seems
logical that a1-AR antagonists could be used in women with
voiding dysfunction (5-8). However, little clinical evidence
is available to indicate that a1-AR antagonists are effective
in female patients with voiding dysfunction. In this study,
we evaluated the potential therapeutic effects of a1-AR antag-
onists using tamsulosin.
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Efficacy and Safety of Tamsulosin for the Treatment of Non-neurogenic
Voiding Dysfunction in Females: A 8-Week Prospective Study
We evaluated the therapeutic effects of tamsulosin for women with non-neurogenic
voiding dysfunction. Women who had voiding dysfunctions for at least 3 months
were included. Inclusion criteria were age ≥18 yr, International Prostate Symptom
Score (IPSS) of ≥15, and maximum flow rate (Qmax) of ≥12 mL/sec and/or postvoid
residuals (PVR) of ≥150 mL. Patients with neurogenic voiding dysfunction or ana-
tomical bladder outlet obstruction were excluded. All patients were classified accord-
ing to the Blaivas-Groutz nomogram as having no or mild obstruction (group A) or
moderate or severe obstruction (group B). After 8 weeks of treatment, treatment
outcomes and adverse effects were evaluated. One hundred and six patients were
evaluable (70 in group A, 36 in group B). After treatments, mean IPSS, bother scores,
Qmax, PVR, diurnal and nocturnal micturition frequencies and scored form of the Bris-
tol Female Lower Urinary Tract Symptoms questionnaire (BFLUTS-SF) were changed
significantly. Eighty-nine patients (84%) reported that the treatment was beneficial.
The proportion of patients reported that their bladder symptoms caused ‘‘moderate
to many severe problems’’ were significantly decreased. No significant difference
were observed between the groups in terms of IPSS, bother score, Qmax, PVR, mic-
turition frequency, and BFLUTS-SF changes. Adverse effects related to medication
were dizziness (n=3), de novo stress urinary incontinence (SUI) (n=3), aggravation
of underlying SUI (n=1), fatigue (n=1). Tamsulosin was found to be effective in female
patients with voiding dysfunction regardless of obstruction grade.
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Study patients
Female patients who had suffered from symptoms of void-
ing dysfunctions for at least 3 months were enrolled in this
prospective, open label, multi-center study. The inclusion
criteria used were; age ≥18 yr, international prostate symp-
tom score (IPSS) ≥15, and maximum flow rate (Qmax) ≤12
mL/sec and/or postvoid residuals (PVR) ≥150 mL. Patients
with possible neurogenic voiding dysfunction or anatomical
bladder outlet obstruction (e.g., urethral stricture, bladder
neck contracture, bladder calculi, bladder tumor, severe pelvic
organ prolapse, previous incontinence surgery, urethral diver-
ticulum, etc.) were excluded. Patients with active urinary
tract infection (UTI), history of recurrent UTIs (symptomat-
ic UTIs ≥4 times in the last year), suspected interstitial cys-
titis, previous surgical procedures related to incontinence or
cystocele, medications of alpha-1 blockers and/or anticholin-
ergics within 7 days before the enrollment, estrogen replace-
ment started within 2 months, and the electrostimulation
and/or bladder training within the 14 days proceeding the
enrollment were excluded from this study. All patients were
informed about the study purpose and protocol and provid-
ed consents.
Patient treatment and assessment
A tamsulosin was initiated at 0.2 mg once daily and main-
tained for 8 weeks. Medications, such as cholinergic drugs
(e.g. bethanechol chloride), and other a-AR antagonists, were
not permitted throughout the 8 week trial period. Before
treatment, all patients underwent an urological evaluation
that included medical history taking, pelvic examination, a
neurourologic examination, urinalysis, urine culture, and a
pressure-flow study (PFS), and all patients maintained a 3-
day voiding diary. Urodynamic studies were performed accord-
ing to the recommendations of the International Continence
Society (ICS) (9).
The efficacy analysis included all patients who received at
least one dose of study drug, had efficacy data available from
the baseline and at least one on-treatment visit, and were
compliant with study medication more than 75%. Treatment
outcomes were evaluated using IPSS, bother scores, Qmax, PVR,
number of micturitions (including 24 hr-, diurnal and noc-
turnal frequencies), scored form of the Bristol Female Lower
Urinary Tract Symptoms questionnaire (BFLUTS-SF) (10),
the patient’s perception of bladder condition, and patient’s
global impression of improvement. The patient’s perception
of bladder condition was assessed by the use of a six point
ordered categorical scale: no problems at all, some very minor
problems, some minor problems, (some) moderate problems,
severe problems, and many severe problems. The patient’s
perception of treatment benefit was assessed by the use of an
ordered categorical scale. The investigator performed the assess-
ment by questioning the patient in two steps. The first ques-
tion asked was ‘‘Have you had any benefit from your treat-
ment?’’ with the alternatives for the patient to answer ‘yes’
or ‘no’. If the answer was ‘yes’, the patient was asked to grade
the benefit into ‘little benefit’ or ‘much benefit’. Tolerability
was evaluated according to adverse event reports.
The Blaivas-Groutz nomogram was used to grade outflow
obstruction (11), and study subjects were divided into two
groups according to obstruction severity (Fig. 1). Patients
with no or mild obstruction were allocated to group A and
those with moderate or severe obstruction to group B. Treat-
ment outcomes of these two groups were compared.
Statistical analysis
Statistical analyses were performed using the paired t-test
for normally distributed data and using the Wilcoxon’s signed-
ranks test for skewed data to compare pre- to post-treatment
changes in the following; IPSS, bother score, Qmax, PVR, mic-
turition frequency, BFLUTS-SF. The Student’s t-test was used
to compare the results of the two groups at presentation and
differences between them when data was normally distribut-
ed, and the Mann-Whitney test was used to analyze skewed
data. Changes in the patient’s perception of bladder condition
after treatment were analyzed using non-parametric methods.
Pvalues of <0.05 were considered statistically significant.
RESULTS
One hundred and thirteen patients were screened and 106
patients were evaluated after 8 weeks of treatment. Mean
patient age was 52.9 yr (range, 21-80 yr). Chief complaints
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Fig. 1. Classification of the study subjects using a bladder outlet
obstruction nomogram as devised by Blaivas and Groutz; Group
A-no obstruction or mild obstruction, Group B-moderate obstruc-
tion or severe obstruction. 
Pdetmax, maximum detrusor pressure; FreeQmax, maximum flow rate
without catheter insertion.
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Group Bwere slow stream (79.3%), increased frequency (70.8%), feel-
ing of incomplete emptying (48.1%), nocturia (34.9%), urgen-
cy (32.1%), and abdominal straining (21.7%). Twenty (18.9
%) women had mild stress urinary incontinence (SUI). Accord-
ing to the Blaivas-Groutz nomogram, 30 patients had no
obstruction (28.3%), 40 mild obstruction (37.7%), 30 mod-
erate obstruction (28.3%), and 6 severe obstruction (5.7%),
respectively (Fig. 1).
After 8-week of treatment, mean IPSS decreased signifi-
cantly from 23.9±6.09 to 16.1±8.17 and storage symp-
toms and voiding symptoms were also improved (Table 1). In
72 patients (67.9%), IPSS decreased by more than 5 points.
Bother scores changed significantly as well. Qmax was increased
significantly from 10.2±2.79 to 13.5±5.65 and PVR was
reduced (P<0.01). Thirty-five (33.0%) patients showed Qmax
increases of more than 50%. According to 3-day voiding
diaries, total, diurnal and nocturnal micturition frequencies
were significantly reduced. However, functional bladder capac-
ities were unchanged (Table 2). BFLUTS-SF total score was
significantly decreased from 21.2 to 16.4 (P<0.001) and
domain scores of voiding, filling, sexual function and quali-
ty of life were also decreased while domain scores of inconti-
nence were not improved significantly (Table 3).
Table 4 shows the baseline parameters of patients in both
groups according to the Blaivas-Groutz nomogram. Bother
scores, PVR, total and diurnal micturition frequencies and
BFLUTS-SF were more severe in patients with no or mild
obstruction. Age, IPSS, Qmax, nocturnal micturition frequen-
cies, and functional bladder capacity were not different in the
two groups. Comparisons of percentage changes observed for
continuous variables of the two groups are shown in Fig. 2.
No significant differences between the two groups were ob-
served in terms of changes in IPSS (including voiding and
storage scores), bother scores, Qmax, PVR, total, diurnal or
nocturnal micturition frequencies and BFLUTS-SF (includ-
ing sub-domain scores).
In the patient’s perception of bladder condition, the pro-
portion of patients who reported that their bladder symptoms
caused ‘moderate to many severe problems’ were 71.7% (76
cases) before treatment and significantly decreased to 46.2%
(49 cases) after treatment (Fig. 3). In the patient’s perception
of treatment benefit, 89 patients (84.0%) reported that the
treatment was beneficial (Fig. 4). Adverse effects related to
medication were dizziness (3 cases), de novo stress urinary
incontinence (3 cases), aggravation of underlying stress uri-
nary incontinence (1 case), and fatigue (1 case). All the adverse
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*paired t-test; 
� Wilcoxon signed ranks test.
IPSS, international prostate symptom score. 
Baseline Parameters 8-week treatment P value
IPSS (sum)  23.89±6.09 16.14±8.17 <0.001*
Storage symptom 9.10±3.66 6.58±3.86 <0.001
�
Voiding symptom 14.78±3.99 9.56±5.48 <0.001*
Bother score 4.79±0.96 3.73±1.40 <0.001
�
Maximum flow rate  10.15±2.79 13.47±5.65 <0.001*
(mL/sec)
Post-void residual (mL)  69.13±85.45 39.88±48.39 <0.001*
Table 1. Changes in symptom scores including bother score and
urodynamic parameters after 8 weeks treatment of tamsulosin
*Wilcoxon signed ranks test.
Baseline 8-week treatment P value
Micturition frequency/24 hr 10.7±3.93 9.33±3.77 <0.001*
Daytime frequency 8.99±3.34 7.84±3.04 <0.001*
Nocturia 1.69±1.33 1.49±1.22 0.024*
Functional bladder capacity 270±100 281±90.7 0.065*
Table 2. Changes in parameters of frequency-volume chart after
treatment
*Wilcoxon signed ranks test.
BFLUTS-SF, Bristol Female Lower Urinary Tract Symptoms question-
naire.  
Baseline 8-week treatment P value
BFLUTS (sum) 21.2±10.4 16.4±9.94 <0.001*
BFLUTS-filling 7.1±3.19 5.4±2.87 <0.001*
BFLUTS-voiding 6.1±3.41 4.5±3.52 <0.001*
BFLUTS-incontinence 2.1±3.52 1.8±3.03 0.426*  
BFLUTS-sex 0.6±1.10 0.4±0.79 0.021*
BFLUTS-QoL 5.2±4.07 4.2±3.67 0.001*
Table 3. Changes in parameters of BFLUTS-SF after treatment
*no or mild obstruction according to Blaivas-Groutz nomogram; 
� moder-
ate or severe obstruction according to Blaivas-Groutz nomogram; 
� Stu-
dent’s t-test;
�Mann-Whitney test.
BFLUTS-SF, Bristol Female Lower Urinary Tract Symptoms question-
naire.  
Group A* Group B
� P value
Age (yr) 52.7±14.2 53.3±12.9 0.904
�
IPSS (sum) 24.4±6.21 22.9±5.82 0.168
�
Voiding symptom 14.8±4.10 14.7±3.85 0.831
�
Storage symptom 9.5±3.63 8.3±3.61 0.161
�
Bother score 4.9±0.98 4.6±0.91 0.003
�
Maximum flow rate (mL/sec) 10.5±2.78 9.6±2.75 0.120
�
Post-void residual (mL)  51.6±62.8 100.6±109.8 0.001
�
Micturition frequency/24 hr 13.3±4.42 10.5±3.19 0.002
�
Daytime frequency 9.5±3.04 7.9±3.66 0.001
�
Nocturia 1.8±1.42 1.5±1.13 0.338
�
Functional bladder capacity 280±107 251±82.2 0.152
�
BFLUTS (sum) 23.0±11.3 17.6±7.25 0.004
�
BFLUTS-filling 7.6±3.36 6.3±2.69 0.048
�
BFLUTS-voiding 6.4±3.48 5.6±3.24 0.278
�
BFLUTS-incontinence 2.3±3.99 1.7±2.34 0.806
�
BFLUTS-sex 0.7±1.28 0.5±0.61 0.721
�
BFLUTS-QoL 6.0±4.29 3.6±3.05 0.001
�
Table 4. Baseline characteristics of two groups according to
severity of obstruction
Parameters
Parameterseffects disappeared after discontinuation of the medication.
No other significant side effect possibly associated with the
study drug was reported.
DISCUSSION
Our results show that the a1-AR antagonist tamsulosin has
a beneficial effect on IPSS scores, bother scores, Qmax, PVR,
diurnal and nocturnal frequencies, and BFLUTS-SF in women
with non-neurogenic voiding dysfunction. This study also
shows that the patient quality of life was improved by treat-
ment and that the majority of patients felt a treatment benefit.
Although many urologists have empirically used a1-AR
antagonists for the treatment of voiding phase dysfunction
in women, little was known about their efficacies. The prob-
able reasons for this are that no standard definition or guide-
line exists for the diagnosis of female voiding dysfunction and
that its mechanism is poorly understood. 
Several studies have suggested therapeutic rationales con-
cerning the use a-AR antagonists for the treatment of void-
ing phase dysfunction in women. An animal study showed
that the densities and affinities of a1-AR in male and female
urethras are similar (6, 8). Nasu et al. (7) performed RNase
protection assays and in situ hybridization to investigate ratios
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Fig. 3. Proportion of patients by the patient’s perception of bladder
condition-pre- vs. post-treatment. White bars include no problems
at all, some very minor problems, and some minor problems. Black
bars include (some) moderate problems, severe problems, and
many severe problems.
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Fig. 4. Proportion of patients by the patient’s perception of treat-
ment benefit- pre- vs. post-treatment. 
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(46%)
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(16%)
Fig. 2. Comparisons of changes in clinical parameters-IPSS (A), Qmax, PVR (B), micturition frequency, FBC (C), BFLUTS-SF (D)-pre- vs. post-
treatment. Values are adjusted using baseline values as covariates. White bars represent group A and black bars group B. 
P, group comparisons of improvement rates after treatment.
IPSS, International Prostate Symptom Score; Qmax, maximum flow rate; PVR, postvoid residual; FBC, functional bladder capacity; QoL, qual-
ity of life.
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P=0.401of a1-AR subtype mRNAs in human proximal urethra, and
their localizations in urethral cross-sections. They found that
a1A was the predominant mRNA subtype in both male and
female urethral samples, and that a1D mRNA was present in
only female samples. In situ hybridization studies showed
no significant differences between male and female urethras
in terms of the cross-sectional distributions of AR subtype
mRNAs. These findings suggest that similar a1-adrenergic
mechanisms control urethral tone in both sexes, and thus, it
appears reasonable to consider the use of a1-AR antagonists
in women with voiding dysfunction, because urethral resis-
tance could be reduced during voiding. An early report des-
cribed the effects of phenoxybenzamine, a nonselective a-AR
antagonist, on women with a spastic striated external urethral
sphincter. The authors found that symptoms were abolished,
and that prolonged fluctuating flow curves were nearly nor-
malized by phenoxybenzamine treatment (12). Some clinical
trials have also suggested that a-AR antagonists may increase
urine flow and decrease PVR in women with bladder outflow
obstruction or a neurological bladder (13, 14). In the current
study, we used tamsulosin (a selective a1A/1D-AR antagonist)
to evaluate the potential therapeutic effects of a1-AR antag-
onists in female patients with voiding phase dysfunction be-
cause a1A and a1D was the predominant subtype in female ure-
thras. Reitz et al. (15) demonstrated that tamsulosin had a
significant relaxing effect on urethral tone in healthy females
in vivo. In that study, microtip pressure transducer catheters
were inserted into the bladder and urethral pressure profiles
were obtained before and after the administration of tamsu-
losin. The oral administration of tamsulosin significantly
reduced the mean and maximal urethral pressure acquired
over the entire urethra. And there was a significant pressure
reduction in all three segments when the proximal, middle
and distal third of the urethra were analysed separately. 
Recent literatures suggest that a-AR antagonists may pro-
vide an effective treatment option for female functional blad-
der outlet obstruction. Kumar et al. (16) reported that 50%
of women with functional functional bladder outlet obstruc-
tion showed improvements in symptoms, Qmax, and PVR after
treatment with a-AR antagonist alone. However, the other
50% of patients underwent bladder neck incision or remained
on clean intermittent self-catheterization due to an inade-
quate response. Pischedda et al. (3) also reported on the effi-
cacy of tamsulosin in female patients with functional blad-
der outlet obstruction. They used the following diagnostic
criteria: Qmax <12 mL/sec, a detrusor voiding pressure at Qmax
of >40 cmH2O, silent electromyographic activity of the exter-
nal sphincter, inappropriate bladder neck funneling by fluo-
roscopy, a normal caliber urethra, and a PVR of ≥60 mL.
Fifty-six percent of their study patients showed significant
improvements in symptoms, Qmax, and PVR after being treat-
ed with tamsulosin (0.4 mg daily) for 1 month.
A small number of reports are available regarding the effi-
cacy of a-AR antagonists for the treatment of detrusor underac-
tivity. Yamanish et al. (4) reported that total IPSS decreased
from 14.7 to 8.4 in female patients with detrusor underac-
tivity after 4 weeks of a-AR antagonist treatment, and they
also found that storage and voiding symptom scores were
reduced. PVR was also significantly decreased from 135 mL
to 87 mL.
Although no agreement has been reached concerning the
diagnostic criteria of functional bladder outlet obstruction
and detrusor underactivity, urodynamic studies, including
pressure-flow studies with/without fluoroscopic examinations,
are likely to be essential for determining bladder and urethral
functions (1, 2, 4, 17). However, these evaluations appear too
invasive to be performed routinely in women with LUTS and
a low flow rate. Recently, two randomized placebo controlled
trials-one for terazosin, one for tamsulosin-reported that a-
AR antagonists could effectively reduce the LUTS in female
patients without any urodynamic evaluations to clarify the
etiology of LUTS (18, 19). In these studies, the inclusion cri-
teria was just total IPSS 8 or greater in female adult. The base-
line Qmax was more than 18.0 mL/sec in each study. The authors
showed that IPSS was significantly improved in a-AR antag-
onists groups compared with placebo groups although there
were no significant differences on Qmax between the two groups.
The authors suggested that a-AR antagonists proved to be
more effective than placebo in patients with female LUTS and
that the improvement in IPSS may not be due to improve-
ments in flow rates (18, 19). In a recent prospective study,
Chang et al. (20) showed that tamsulosin could effectively
improve both IPSS and Qmax in female patients with voiding
difficulty. In 97 patients, IPSS was reduced from 20.2 to 14.8
and Qmax was increased from 10.4 mL/sec to 14.1 mL/sec (P<
0.01) and a good therapeutic response was observed in 35.1%
of patients after 6-week treatment. The authors also demon-
strated that the improvements of IPSS and Qmax were not dif-
ferent between the bladder outlet obstruction (n=33) and
detrusor underactivity group (n=52) in subgroup analysis.
However, in that study, the inclusion criteria was obscure
without the definition of voiding difficulty and much of the
study patients had cormorbidities that might lead to void-
ing difficulties such as diabetes, Parkinsonism, herniation of
intervertebral disc, etc. It suggests that the etiology of void-
ing difficulty was more diverse in that study.
The present study demonstrates that IPSS, bother score,
Qmax, PVR, micturition frequency, and BFLUTS-SF were
improved significantly after tamsulosin treatment in female
patients with non-neurogenic voiding dysfunction who had
LUTS and a low flow rate. This study also shows that changes
in these parameters were similarly observed in those with
different obstruction severities. Thus, the use of a1-AR antag-
onists in women with non-neurogenic voiding dysfunction
appears reasonable, because they would reduce urethral resis-
tance during micturition regardless of the degree of obstruc-
tion. In the current study, 72 (67.9%) patients showed an
IPSS decrease of more than 5 points and 35 (33.0%) showed
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We believe that this method represents a good therapeutic
approach to female voiding dysfunction, before considering
invasive tests, such as, pressure-flow studies and fluoroscop-
ic examination, or more invasive treatment modalities, such
as, clean intermittent self-catheterization and bladder neck
incision. Nevertheless, tamsulosin treatment was found to
be effective in some patients but not in others. Although we
cannot provide a clear reason, this variability may be due to
different underlying pathologies affecting micturition mech-
anisms.
The limitation of this study is that it was not a placebo-
controlled study but an observational study, and thus, place-
bo effects may have affected symptom scores and subjective
satisfaction ratings. However, we consider that this study is
valuable because this study is performed for the relatively large
scale of patients and shows that the a-AR antagonists is effec-
tive for the women with low flow rate and LUTS regardless
of obstruction severity. Our findings indicate that a1-AR an-
tagonists offer an initial treatment option for women with a
non-neurogenic voiding dysfunction. To further determine
the efficacy of a1-AR antagonists in women with voiding dys-
function a long-term, randomized, controlled study is required
to compare the efficacy of a1-AR antagonists versus placebo
treatment.
Tamsulosin demonstrated effectiveness in female patients
with voiding dysfunction and its efficacies were independent
of obstruction grade. A majority of patients showed subjec-
tive and objective improvements and were satisfied with treat-
ment. Our findings suggest that a1-AR antagonists offer an
initial treatment option for female non-neurogenic voiding
dysfunction. 
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